Nuvo Pharmaceuticals Inc MRVFF

RE:RE:P2 contract extended to 2029

[consultant99]

Based on what analysis?

Voltaren sales remain strong years after coming on the market. It has a brand value as does Tylenol; a medicine cabinet staple.

If and when generics enter the market Horizon might have to discount the retail price. Because Nuvo management took the deal with no royalty payments, there is no risk to Nuvo revenues from lower retail prices. Further if Horizon ever lowers their prices and retail sales increase Nuvo revenues would increase because they make money on each bottle sold.

The big potential uptic in revenues for Nuvo will occur when Pennsaid is sold ex-US. There is no way any buy out in 2016 will give Nuvo shareholders max value for their shares when these sales will not begin until 2017 in the EU, Canada, & Australia (as per management).